ROIV — Roivant Sciences Ltd. stock price, charts and financials

QT75Roivant Sciences Ltd.

Roivant Sciences Ltd. (NASDAQ: ROIV) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
36.06
-0.28-0.78%
OverviewShort InterestFilings
ROIVQT75Roivant Sciences Ltd.·NASDAQ
36.06-0.78%
News
Down 0.8% — Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon (seekingalpha.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Earnings big miss — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
INCY+1.24%$122.05INSM+1.63%$133.23ALNY-0.35%$218.42MRNA+0.54%$59.49BNTX-0.15%$93.53UTHR-1.83%$528.97GMAB-1.20%$30.88BBIO+0.57%$84.96
Snapshot
Index-P/E-EPS (ttm)-0.51Insider Own23.16%Shs Outstand722.41MPerf Week7.17%
Market Cap26.25BForward P/E-EPS next Y-1.05Insider Trans-8.47%Shs Float577.47MPerf Month-1.28%
Enterprise Value25.11BPEG0.80EPS next Q-Inst Own-Short Float6.35%Perf Quarter28.50%
Income-267.77MP/S-EPS this Y-145.35%Inst Trans-Short Ratio6.13Perf Half Y71.90%
Sales7.53MP/B6.19EPS next Y16.37%ROA-5.02%Short Interest36.70MPerf YTD67.47%
Book/sh-P/C-EPS next 5Y-ROE-6.12%52W High36.71 -1.78%Perf Year211.93%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-27.14%52W Low10.82 233.39%Perf 3Y207.71%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-37.00% -19.73%Gross Margin81.21%Volatility3.79% 3.43%Perf 5Y266.70%
Dividend TTM-EV/Sales-EPS Y/Y TTM-112.50%Oper. Margin-18140.92%ATR (14)1.29Perf 10Y-
Dividend Ex-Date-Quick Ratio16.72Sales Y/Y TTM-68.97%Profit Margin-3534.88%RSI (14)62.14Recom2.07
Dividend Gr. 3/5Y-Current Ratio16.72EPS Q/Q3.72%SMA205.24%Beta1.10Target Price38.33
Payout0.00%Debt/Eq0.03Sales Q/Q-62.50%SMA5010.13%Rel Volume1.11Prev Close36.34
Employees721LT Debt/Eq0.02EarningsNov 09SMA20035.27%Avg Volume6.00MPrice36.06
IPO DateDec 08, 2020Option/ShortYes / YesEPS/Sales Surpr.3.49% -26.20%Net Debt/EBITDA4.06Volume6,671,536Change-0.78%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-07-26ReiteratedH.C. WainwrightBuy$34 → $41
May-26-26ReiteratedGuggenheimBuy$30 → $36
May-21-26ReiteratedCowen & Co.Outperform$38 → $41
May-21-26ReiteratedLeerink PartnersOutperform$32 → $42
Apr-16-26ReiteratedPiper SandlerOverweight$20 → $40
Mar-04-26ReiteratedHC Wainwright & Co.Buy$33 → $34
Feb-10-26ReiteratedHC Wainwright & Co.Buy$26 → $33
Feb-09-26ReiteratedJefferiesBuy$24 → $30
Feb-09-26ReiteratedGuggenheimBuy$28 → $30
Dec-18-25ReiteratedGuggenheimBuy$25 → $28
Latest News
Aug-08-26
Aug-08-2608:05AM
Roivant Sciences: The Balance Sheet Has Become A Strategic Weaponseekingalpha.com
Aug-07-26
Aug-07-2607:04AM
Roivant Sciences Q1 Earnings Call Highlightsmarketbeat.com
Aug-06-26
Aug-06-2607:02PM
Roivant Sciences Ltd (ROIV) (Q1 2026) Earnings Call Highlights: Strategic Advances and Strong ...Yahoo
04:24PM
Roivant Sciences Ltd. (ROIV) Q1 2026 Earnings Call Transcriptseekingalpha.com
10:51AM
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimateszacks.com
07:00AM
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026globenewswire.com
07:00AM
Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Updateglobenewswire.com
07:00AM
Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)globenewswire.com
Aug-04-26
Aug-04-2604:47AM
Roivant Sciences Ltd. $ROIV Shares Purchased by California State Teachers Retirement Systemdefenseworld.net
Jul-29-26
Jul-29-2612:25PM
Fortrea Holdings Inc. (FTRE) Surpasses Q2 Earnings and Revenue EstimatesYahoo
Jul-25-26
Jul-25-2605:15AM
Bank of Nova Scotia Cuts Stake in Roivant Sciences Ltd. $ROIVdefenseworld.net
04:21AM
Allspring Global Investments Holdings LLC Buys New Stake in Roivant Sciences Ltd. $ROIVdefenseworld.net
Jul-23-26
Jul-23-2608:05PM
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026Yahoo
04:05PM
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026globenewswire.com
Jul-16-26
Jul-16-2611:30AM
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to ShareholdersYahoo
Company

Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
3/31/2026
FY 2024
3/31/2025
FY 2023
3/31/2024
FY 2022
3/31/2023
FY 2021
3/31/2022
FY 2020
3/31/2021
FY 2019
3/31/2020
Total Revenue8829—————
Cost of Goods Sold Incl. D&A111—————
Gross Profit5728—————
Selling, General and Administrative Excl. Other642610591—————
Research and Development731682550—————
Other Operating Expense-101—————
Operating Income-1,366-1,285-1,114—————
Interest Expense
000—————
Unusual Expense
————————
Non-Operating Income (Expense)1,0761,021432—————
Net Income Before Taxes-290-265-682—————
Income Taxes12413348—————
Consolidated Net Income-267-300-172—————
Net Income From Continuing Operations-415-398-730—————
Net Income-267-300-172—————
EPS (Recurring)-0.38-0.43-0.24—————
EPS (Basic, Before Extraordinaries)-0.38-0.43-0.24—————
EPS (Diluted)-0.44-0.43-0.24—————
EBITDA-281-261-668—————
Other After Tax Adjustments
————————
Stock Option Compensation Expense
————————
Price To Earnings Ratio
————————
Price To Sales Ratio3,249.622,402.98252.25—————
Gross Margin62.5087.5096.55—————
Operating Margin-17,075.00-16,062.50-3,841.38—————
Net Margin-3,337.50-3,750.00-593.10—————
Shares Outstanding721694725—————
Market Capitalization25,99719,2247,315—————
Operating Lease Expense
————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$40.72$32.25$23.78$15.30$6.83● Close Price0.00M67.96M135.93M203.89M271.86MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Venker EricPresident & Immunovant CEOJul 27 '26Option Exercise3.85200,000770,0001,813,063Jul 29
Venker EricPresident & Immunovant CEOJul 27 '26Sale34.95200,0006,990,0001,613,063Jul 29
Fitzgerald MeghanDirectorJun 30 '26Option Exercise8.8010,00088,00052,963Jul 02
Fitzgerald MeghanDirectorJun 30 '26Sale34.9010,000349,00042,963Jul 02
Epperly Melissa B,DirectorJun 29 '26Option Exercise4.4617,75079,16534,224Jul 01
Epperly Melissa B,DirectorJun 29 '26Sale34.3817,750610,25216,474Jul 01
Gold Daniel AllenDirectorJun 30 '26Sale35.2812,380436,76613,689,166Jun 30
QVT Financial LPother: Director by DeputizationJun 30 '26Sale35.2812,380436,76613,689,166Jun 30
MANCHESTER KEITH SDirectorJun 30 '26Sale35.44212,3807,526,7661,748,403Jun 30
Gold Daniel AllenDirectorJun 29 '26Sale34.55800,00027,642,00013,701,546Jun 30
QVT Financial LPother: Director by DeputizationJun 29 '26Sale34.55800,00027,642,00013,701,546Jun 30
MANCHESTER KEITH SDirectorJun 29 '26Sale34.55800,00027,642,00013,701,546Jun 30
QVT Financial LPother: Director by DeputizationJun 26 '26Sale34.00625,78321,275,30914,501,546Jun 30
MANCHESTER KEITH SDirectorJun 26 '26Sale34.00625,78321,275,30914,501,546Jun 30
Gold Daniel AllenDirectorJun 26 '26Sale34.00625,78321,275,30914,501,546Jun 30
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.